No Data
RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3
RBC Capital analyst Brian Abrahams maintains $Karyopharm Therapeutics(KPTI.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 49
Karyopharm Therapeutics(KPTI.US) Director Sells US$785.03K in Common Stock
$Karyopharm Therapeutics(KPTI.US)$ Director PAKIANATHAN DEEPIKA sold 818.04K shares of common stock on Jun 5, 6, 7, 2024 at an average price of $0.9596 for a total value of $785.03K.Source: Announceme
Karyopharm Therapeutics(KPTI.US) Director Sells US$880.69K in Common Stock
$Karyopharm Therapeutics(KPTI.US)$ Director PAKIANATHAN DEEPIKA sold 906.18K shares of common stock on May 31, Jun 3, 4, 2024 at an average price of $0.9719 for a total value of $880.69K.Source: Annou
Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., June 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company g
Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024
Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024